Evommune: advancing ex-Dermira assets, screening for new programs using human tissue

With enough cash to generate Phase IIa data around three targets of interest, Evommune is continuing to advance programs that formerly belonged to Dermira while also discovering new molecules via its human skin tissue-derived screening model.

Palo Alto, Calif.-based Evommune Inc. closed a $50 million series B round this week, adding more fuel to develop a lead clinical therapy targeting IRAK4 as well as two preclinical programs. The biotech in-licensed two of the three from Eli Lilly and Co. (NYSE:LLY), which acquired Dermira Inc. in 2020 for $1.1 billion; several Evommune employees, including founding President and CEO Luis Peña, were on Dermira’s team...